SCHEDULE: Voss Capital Discloses Stake in Rein Therapeutics

Voss Capital and affiliated entities report beneficial ownership of 6.6% of Rein Therapeutics' common stock as of June 30, 2026.

Summary

• Voss Capital, along with its associated funds and managing member Travis W. Cocke, has disclosed a beneficial ownership stake of 6.6% in Rein Therapeutics, Inc.
• This stake amounts to 5,656,957 shares of common stock.
• The disclosure was made on a Schedule 13G filing, indicating the shares were not acquired for the purpose of influencing control of the issuer.
• The filing details the ownership breakdown across Voss Value Master Fund, L.P. (1.2%), Voss Value-Oriented Special Situations Fund, L.P. (0.6%), Voss Advisors GP, LLC (1.8%), Voss Capital, L.P. (6.6%), and Travis W. Cocke (6.6%).
• The total number of outstanding shares of Rein Therapeutics' common stock as of May 13, 2026, was 85,539,032.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It is a routine disclosure of a significant investment stake, providing transparency without offering new operational or financial performance data for Rein Therapeutics.

Positives

• Voss Capital has taken a significant stake in Rein Therapeutics, potentially signaling confidence in the company's future prospects.
• The disclosure is a standard regulatory filing, providing transparency to the market regarding significant shareholdings.

Risks

• The filing does not contain specific forward-looking statements or risk factors beyond the standard certification that the shares are not held for the purpose of influencing control.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Rein Therapeutics. It is a disclosure of beneficial ownership by Voss Capital.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Voss Capital's strategic interest in Rein Therapeutics, a biotechnology company, which aligns with broader investment trends in the sector.

Stakeholder Impact

• Shareholders: Increased transparency regarding significant ownership, potentially influencing market perception and trading activity.
• Management of Rein Therapeutics: Awareness of a substantial institutional investor's interest.
• Voss Capital Investors: Confirmation of their investment strategy and holdings in Rein Therapeutics.

Next Steps

• Voss Capital will continue to hold its stake in Rein Therapeutics, subject to market conditions and its investment strategy.
• Rein Therapeutics may continue its operations and strategic initiatives as previously disclosed in its other SEC filings.

Key Dates

Keywords

Rein Therapeutics, Voss Capital, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment, Shareholder